Literature DB >> 13197750

Pyrazinamide-isoniazid in tuberculosis. I. Results in 58 patients with pulmonary lesions one year after the start of therapy.

C MUSCHENHEIM, W McDERMOTT, R McCUNE, K DEUSCHLE, L ORMOND, R TOMPSETT.   

Abstract

Entities:  

Keywords:  NICOTINIC ACID ISOMERS/therapeutic use; NICOTINIC ACID/derivatives; TUBERCULOSIS, PULMONARY/therapy

Mesh：

Substances：

Year:  1954        PMID： 13197750     DOI： 10.1164/art.1954.70.4.743

Source DB:  PubMed          Journal:  Am Rev Tuberc        ISSN： 0096-0381


× No keyword cloud information.
  5 in total

1.  A review of 138 cases of closure of tuberculous lung cavities under chemotherapy.

Authors:  J D ROSS; D T KAY
Journal:  Thorax       Date:  1956-03       Impact factor: 9.139

2.  Antimicrobial therapy of pulmonary tuberculosis.

Authors:  W McDermott
Journal:  Bull World Health Organ       Date:  1960       Impact factor: 9.408

3.  Optimising pyrazinamide for the treatment of tuberculosis.

Authors:  Nan Zhang; Radojka M Savic; Martin J Boeree; Charles A Peloquin; Marc Weiner; Norbert Heinrich; Erin Bliven-Sizemore; Patrick P J Phillips; Michael Hoelscher; William Whitworth; Glenn Morlock; James Posey; Jason E Stout; William Mac Kenzie; Robert Aarnoutse; Kelly E Dooley
Journal:  Eur Respir J       Date:  2021-07-20       Impact factor: 33.795

4.  Quality of reporting of outcomes in phase III studies of pulmonary tuberculosis: a systematic review.

Authors:  Laura Jayne Bonnett; Gie Ken-Dror; Geraint Rhys Davies
Journal:  Trials       Date:  2018-02-21       Impact factor: 2.279

Review 5.  Impact of the host environment on the antitubercular action of pyrazinamide.

Authors:  Elise A Lamont; Anthony D Baughn
Journal:  EBioMedicine       Date:  2019-10-25       Impact factor: 8.143
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.